RDHL Stock Analysis: Buy, Sell, or Hold?
RDHL - Redhill Biopharma Ltd.
$0.61
-0.02 (-3.17%)
âŧ
5d:
+4.27%
30d:
-3.68%
90d:
-37.75%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Apr 09, 2026
0d
Get Alerted When RDHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RDHL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RDHL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: RDHL is currently trading at $0.61, which is considered slightly low relative to its 30-day fair value range of $0.60 to $0.69.
Technical Outlook: Technically, RDHL is in a strong downtrend. Immediate support is located at $0.57, while resistance sits at $0.65. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: RDHL scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19000.00 (+3015773.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RDHL is in a strong downtrend. Immediate support is located at $0.57, while resistance sits at $0.65. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: RDHL scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19000.00 (+3015773.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.60 -
$0.69
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 3015773.0% below Wall St target ($19000.00)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.60 -
$0.69
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.57
Resistance Level
$0.65
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1428.57
Wall Street Target
$19000.00
(+3015773.0%)
Revenue Growth (YoY)
58.6%
Profit Margin
-150.0%
Share & Embed Analysis
Last updated: August 24, 2026 3:05 PM ET
Data refreshes hourly during market hours. Next update: 4:05 PM
Data refreshes hourly during market hours. Next update: 4:05 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RDHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilead Raday
SELL
15740000 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
